Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

Barclays analyst Etzer Darout has maintained an Equal-Weight rating on Summit Therapeutics (NASDAQ: SMMT) while raising the price target from $18 to $20. This adjustment reflects Barclays' updated outlook on the company's performance.